Foundayo Cuts Sleep Apnea Events ~44%, Lilly Plans Year-End FDA Filing
LLY sits 64% above its 52-week low of $850.51 on light trading volume (0.2× avg).
Summary
Foundayo (orforglipron), Lilly's oral GLP-1, hit its primary endpoint in a late-stage obstructive sleep apnea program, cutting breathing interruptions by about 44% in patients not on PAP therapy and nearly 28% in those using it. At 52 weeks, roughly 32% of non-PAP patients and nearly 20% of PAP users reached remission or mild disease, with side effects consistent with prior trials (mostly mild-to-moderate GI). Lilly will file for the sleep apnea indication with the FDA by year-end, opening a label expansion beyond obesity for a drug that already showed cardiovascular benefit in ACHIEVE-4 in September. Shares rose 3.1% to $1,396.02, near the 52-week high of $1,453, on a stock that has already run hard through Q3's 39% revenue growth and the retatrutide head-to-head win over Ozempic. The sleep apnea label would add a large, under-treated population with clear cardiovascular overlap — incremental revenue on top of the obesity franchise rather than a new pipeline bet. Watch the FDA submission by year-end and any subsequent review timeline.
At the time of this announcement, LLY was trading at $1,394.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3T. The 52-week trading range was $850.51 to $1,453.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.